Drug Type Antibody drug conjugate (ADC) |
Synonyms DB 1317, DB1317 |
Target |
Action inhibitors |
Mechanism ADAM9 inhibitors(ADAM metallopeptidase domain 9 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 01 Sep 2025 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Australia | 01 Sep 2025 | |
Castration-Resistant Prostatic Cancer | Phase 1 | United States | 01 Sep 2025 | |
Castration-Resistant Prostatic Cancer | Phase 1 | Australia | 01 Sep 2025 | |
Solid tumor | Preclinical | China | 27 May 2024 |